Peg-IFNα combined with hepatitis B vaccination contributes to HBsAg seroconversion and improved immune function

The purpose of this study was to investigate immunological variations between a group that received the hepatitis B vaccine and a non-vaccine group. We focused on a cohort that achieved HBsAg seroclearance after Peg-IFNα treatment of CHB. We enrolled twenty-eight individuals who achieved HBsAg seroc...

Full description

Saved in:
Bibliographic Details
Published in:Virology journal 2024-03, Vol.21 (1), p.77-77, Article 77
Main Authors: Liu, Yisi, Ren, Shan, Ma, Lina, Lin, Xiao, Lu, Junfeng, Cao, Zhenhuan, Zheng, Sujun, Hu, Zhongjie, Xu, Xiaoxue, Chen, Xinyue
Format: Article
Language:English
Subjects:
Antibodies
Antiviral Agents - therapeutic use
CD27 antigen
CD80 antigen
Cell surface
Cytokines
Effectiveness
Functional cure
HBsAg seroconversion
Helper cells
Hepatitis B
Hepatitis B Antibodies
Hepatitis B e Antigens
Hepatitis B surface antigen
Hepatitis B Surface Antigens
Hepatitis B vaccine
Hepatitis B Vaccines - therapeutic use
Hepatitis B, Chronic - drug therapy
Humans
Humoral immunity
Immune response
Immunity
Immunization
Immunoglobulin G
Infections
Interferon therapy
Interferon-alpha - therapeutic use
Interleukins
Liver cancer
Lymphocytes
Lymphocytes B
Lymphocytes T
Medical research
Plasma cells
Polyethylene Glycols - therapeutic use
Seroconversion
Software
Tumor necrosis factor-TNF
Vaccination
Vaccines
α-Interferon
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The purpose of this study was to investigate immunological variations between a group that received the hepatitis B vaccine and a non-vaccine group. We focused on a cohort that achieved HBsAg seroclearance after Peg-IFNα treatment of CHB. We enrolled twenty-eight individuals who achieved HBsAg seroclearance after Peg-IFNα treatment. They were divided into two groups: a vaccine group (n = 14) and a non-vaccine group (n = 14). We assessed lymphocyte subpopulations, B cell- and T cell-surface costimulatory/inhibitory factors, cytokines and immunoglobulin levels were detected at different time points to explore immune-function differences between both groups. The seroconversion rate in the vaccine group at 24 weeks post-vaccination was 100%, which was significantly higher (p = 0.006) than that of the non-vaccine group (50%). Additionally, more individuals in the vaccine group exhibited anti-HBs levels exceeding 100 IUs/L and 300 IUs/L compared to the non-vaccine group (p 
ISSN:1743-422X
1743-422X
DOI:10.1186/s12985-024-02344-8